Peregrine Pharmaceuticals, Inc. (PPHM) ended last trading session with a change of 17.35 percent. It trades at an average volume of 3.77M shares versus 6.24M shares recorded at the end of last trading session. The share price of $0.76 is at a distance of 172.43 percent from its 52-week low and down 0.37 percent versus its peak. The company has a market cap of $183.96M and currently has 241.17M shares outstanding. The share price is currently 38.94 percent versus its SMA20, 89.66 percent versus its SMA50, and 101.03 percent versus its SMA200. The stock has a weekly performance of 7.44 percent and is 146.06 percent year-to-date as of the recent close.
March 13, 2017 — Peregrine Pharmaceuticals, Inc. (PPHM) a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies, and advancing its proprietary R&D pipeline, announced financial results for the third quarter of fiscal year (FY) 2017 ended January 31, 2017, and provided an update on its contract manufacturing business, preclinical and clinical pipeline, and other corporate developments.
Catabasis Pharmaceuticals, Inc. (CATB) recently recorded -18.14 percent change and currently at $1.67 is 54.63 percent away from its 52-week low and down -78.83 percent versus its peak. It has a past 5-day performance of 41.53 percent and trades at an average volume of 1.57M shares. The stock has a 1-month performance of 35.77 percent and is -53.74 percent year-to-date as of the recent close. There were about 12.16M shares outstanding which made its market cap $20.31M. The share price is currently 33.17 percent versus its SMA20, -35.52 percent versus its SMA50, and -57.69 percent versus its SMA200.
On March 13, 2017 Catabasis Pharmaceuticals, Inc. (CATB) announced that it will present data from Part B of the MoveDMD trial of edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy (DMD) at the 2017 Muscular Dystrophy Association Scientific Conference to be held March 19 – 22, 2017, in Arlington, VA, at the Hyatt Regency Crystal City.
Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis, will deliver oral and poster presentations titled “MoveDMD: Phase 1/2 trial of Edasalonexent, an NF-kB Inhibitor, in 4- to 7-Year-Old Patients with Duchenne Muscular Dystrophy.” The oral presentation will take place on Wednesday, March 22, 2017 from 11:15am – 11:45am ET. The poster presentations will take place during the poster sessions on Monday, March 20, 2017 from 6:45pm – 8:45pm and Tuesday, March 21, 2017 from 6:30pm – 8:30pm ET.